A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.

A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.

Zhitong Finance02:42 ET

These Funds Made Heady Gains. Thank Nvidia.

Which fund held Nvidia—and how big their stake was—went a long way to determining winners and losers in the quarter. Here's who benefited, and who missed the boat.

Barrons01:00 ET

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst

On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.Once-monthly, Kisunla is th

Benzinga12:13 ET

BMO: Eli Lilly and Co's Alzheimer's drug is expected to generate revenue of $7.1 billion, which is better than Biogen's competitor.

According to BMO reports, eli lilly and co's newly approved Alzheimer's drug donanemab could bring in peak sales of up to $7.1 billion for the company.

Zhitong Finance23:59 ET

Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$8.1 Million in Common Stock

$Eli Lilly and Co(LLY.US)$ 10% Shareholder LILLY ENDOWMENT INC sold 8,848 shares of common stock on Jul 3, 2024 at an average price of $915.309 for a total value of $8.1 million.Source: Announcement W

Moomoo News16:41 ET

Eli Lilly and Co Options Spot-On: On July 3rd, 50,397 Contracts Were Traded, With 279.34K Open Interest

On July 3rd ET, $Eli Lilly and Co(LLY.US)$ had active options trading, with a total trading volume of 50,397 options for the day, of which put options accounted for 41.62% of the total transactions, a

Moomoo News16:30 ET